Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orlance ovarian cancer nucleic acid immunotherapy
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Epidermal
01
Overview
Orlance's ovarian cancer candidate is a preclinical-stage nucleic acid immunotherapy delivered via the proprietary MACH-1 (Microparticle Accelerated Cellular High-delivery) platform. This technology utilizes a needle-free, epidermal powdered gene gun to deliver DNA or RNA-coated gold microparticles directly into the skin's immunologically active epidermal layer. By targeting the abundant antigen-presenting cells in the epidermis, such as Langerhans cells, the therapy aims to induce a robust systemic immune response against ovarian cancer cells. The MACH-1 platform is designed to overcome the delivery challenges associated with traditional nucleic acid therapies, potentially enhancing potency and stability without the need for cold-chain storage.
- Other names
- Orlance ovarian cancer immunotherapy
Beyond the preview
Go deeper on Orlance ovarian cancer nucleic acid immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orlance ovarian cancer nucleic acid immunotherapy.